WO1997007207A1 - Co-precipitant et procede d'extraction d'acides nucleiques - Google Patents
Co-precipitant et procede d'extraction d'acides nucleiques Download PDFInfo
- Publication number
- WO1997007207A1 WO1997007207A1 PCT/JP1996/002263 JP9602263W WO9707207A1 WO 1997007207 A1 WO1997007207 A1 WO 1997007207A1 JP 9602263 W JP9602263 W JP 9602263W WO 9707207 A1 WO9707207 A1 WO 9707207A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- coprecipitant
- nucleic acids
- extracting
- alcohol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
Definitions
- the present invention relates to a biological material such as blood, urine, cerebrospinal fluid, sputum, semen, cells, tissue, and biopsy specimen, and a nucleic acid recovery operation by alcohol treatment in the process of nucleic acid extraction from Z or a test sample. It shows the same behavior as that described above, and precipitates as a visible precipitate by centrifugation, and it relates to a coprecipitant used to recover nucleic acids with high recovery and high reproducibility, and a method for extracting nucleic acids using the coprecipitant. . Background art
- nucleic acid probes have progressed rapidly, and it has become important to simplify sample processing and to purify nucleic acids with high purity by removing impurities other than nucleic acids.
- inadequate purification of the DNA sample will bind the protein to the DNA, and if it contains carbohydrates, it will inhibit the digestion of the DNA by the restriction enzyme. Can not recognize the nucleotide sequence of, and cannot obtain satisfactory results.
- nucleic acid hybridization using a BNA sample satisfactory results cannot be obtained in nucleic acid hybridization if the RNA sample is not sufficiently purified.
- the antibody or avidin used in the reagent may nonspecifically bind to the impurities, resulting in erroneous determination.
- Preparation of purified DNA or UNA usually requires basically four steps. 1) cell lysis, 2) deproteinization and decarboxylation, 3) separation and concentration, 4) washing and purification.
- Cell lysis enzymes such as lysozyme and achromopeptidase and proteinases such as proteinase K are used for cell lysis.
- the cells are destroyed using a detergent such as SDS.
- a detergent such as SDS.
- Microorganisms with strong cell walls, such as tuberculosis bacteria and staphylococci, are physically destroyed using beads or ultrasonic waves.
- cell wall lysing enzymes or proteolytic enzymes may be used in combination with this, or combined with addition of an alkaline surfactant.
- DNA forms an aqueous liquid layer (upper layer) and denatured protein forms a cottony white layer in the middle layer between the aqueous liquid layer and organic liquid layer (lower layer).
- Careful work such as carefully sucking out the DNA layer using a wide-mouthed bit so as not to inhale the white layer and transferring the DNA layer to a new microtube is required. This operation was time-consuming and required skill, which had an adverse effect on the reproducibility of DNA recovery, and also made it difficult to process in large quantities.
- the nucleic acid (DNA or RNA) is precipitated and separated from the aqueous liquid containing the nucleic acid with 100% isoisopropyl alcohol or 100% ethanol.
- isopropyl alcohol final concentration of 50%
- ethanol final concentration of 70%
- nucleic acids are usually purified using 70% ethanol to remove impurities from the separated and concentrated nucleic acids.
- heparin-collected blood is treated with Triton X-100, centrifuged, and sedimented. After adding guanidine isotiosocyanate to There is a method in which DNA is added by adding vanol and then washed with ethanol, and this method can extract DMA within 2 hours.
- CTAB is added to form a complex of nucleic acid and CTAB in an organic solvent, then dissolved in a high salt aqueous solution to dissociate DNA and CTAB, and then ethanol or isopropanol is used.
- This is a method for recovering DNA. Although this method does not use high-risk fuenols, it is actually a lot of centrifugation, washing, and operation is troublesome.
- Pretreatment for eluting nucleic acids from biological material was performed as a gradient (decantion) for purification or as a method that can be sorted by inversion.
- the pretreated biological material is then mixed with a non-hydrophilic, high-density organic liquid containing a thixotropic agent and an aqueous liquid, mixed and centrifuged.
- a so-called agglutination / distribution method has already been proposed for a nucleic acid extraction method in which an aggregated layer is formed and the nucleic acid in the upper layer is separated and extracted (Japanese Patent Application Laid-Open No. 422,738).
- PCR polymerase chain reaction
- f-T-PCR reverse transcription
- the method of combining guanidine thiosinate with phenol and phenol (known as the AGPC method) is widely used for nucleic acid extraction, but special attention should be paid to the extraction of trace amounts of nucleic acids.
- the method is to reliably recover nucleic acids in an alcohol precipitation operation using isoprovir alcohol or ethanol after removing proteins.
- the present invention has been made in view of the above-mentioned problems of the prior art.
- the method comprises the steps of: Has affinity, does not compete with the reverse transcription reaction, does not interfere with the PCR reaction, and allows visualization as a white or blue precipitate while minimizing technical errors while ensuring nucleic acid recovery It is intended to provide a coprecipitant and a method for extracting a nucleic acid using the coprecipitant. Disclosure of the invention
- the coprecipitant of the present invention exhibits the same behavior as nucleic acids in the process of extracting nucleic acids from biological materials and / or test samples by centrifugation, and is white or white when subjected to separation and concentration treatment with various alcohols. It has the property of precipitating as a blue visible precipitate.
- the alcohol isopropyl alcohol or ethanol is used. In a centrifugal separation operation using a centrifuge tube such as a microtube, the precipitate adheres to the bottom of the centrifuge tube.
- the substance to be used as the coprecipitant of the present invention is a starch, which uses amylose, amyctic pectin, or a derivative thereof, which is a component of starch, and converts a small amount of nucleic acid in alcohol precipitation into a white precipitate or a blue precipitate. It is designed to enable visual observation. That is, the substance used as the coprecipitant of the present invention is preferably a long-chain glucose-binding polysaccharide, a dye-modified long-chain glucose-binding polysaccharide, or a derivative thereof.
- long-chain glucose-binding polysaccharide used in the present invention examples include starch and starch derivatives such as Soluble Starch, Corn Starch, and Potato Starch. , Potato soluble Starch, Wheel starch (Wheal Starch), Starch Azure (Starch Azure) and the like.
- starch constituents and their derivatives Corn Amylopectin, Potato Amy lopectin, Amylopectin Anthrani late, Amylopectin (Amylo pectin Azure), Insoluble Cone Amylopec tin, Soluble Potato Amylopectin, Cone Amylose, Potato Amylos, Amylopectin It is preferable to use Azumi (Amyiose Azure).
- Azur is a dye suitable as a dye to be modified for the dye-modified long-chain glucose-binding polysaccharide.
- Azure examples include Remazol Brilliant Blue R, Remazol Brilliant Blue- D -Xylan, and Remazol Brilliant Violet 5 Earl. Etc. can be used.
- Suitable aqueous solutions for dissolving the coprecipitant include distilled water or TE buffer (generally 5 OmM trishydroxymethylaminoamino-hydrochloric acid buffer PH8.0 ⁇ 20 mM EDTA), etc. Buffer salts, sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium acetate. Ammonia chloride. Inorganic salts such as ammonium acetate, ammonium sulfate, etc., and their mixtures are usually about 0.1M to 10.0M. Range concentration Used in. The concentration of the coprecipitant used in the present invention is 0.5 to 100 g / rak, preferably 5 to 50 g / ml.
- the pretreated biological material and / or the protein of the test sample are subjected to a pretreatment.
- the aqueous liquid containing the nucleic acid is separated, and an alcohol such as isopropyl alcohol or ethanol is added to the separated aqueous liquid containing the nucleic acid, mixed and centrifuged to separate and concentrate the nucleic acid.
- the above-mentioned coprecipitant is used as a coprecipitant that precipitates with the nucleic acid.
- Examples of the protein removal treatment in the above method include phase separation and extraction with phenol, solubilization of proteins with a hot-dip bioagent, formation of a nucleic acid complex with a cationic surfactant, capture of nucleic acids with a glass filter, or nucleic acid with magnetic beads. Can be used.
- the pretreated biological material and / or the test sample are thixotropic. Mouth big: Non-hydrophilic, high specific gravity organic liquid containing an adhesive and aqueous liquid are added and mixed, and after centrifugation, nucleic acid is contained by forming a non-fluid aggregated layer at the interface between the upper and lower layers The upper layer is easily separated, and an alcohol such as isopropyl alcohol or ethanol is added to the separated aqueous liquid containing the nucleic acid, mixed, centrifuged, and the nucleic acid is separated and concentrated. It uses a coprecipitant.
- This method for extracting nucleic acids is generally called an agglutination distribution method.
- the biological material and / or test killing referred to in the present invention refers to blood, urine, cerebrospinal fluid, sputum, semen, cells, tissues, biopsy specimens, yeast, fungi, bacteria, viruses, cultured cells, etc. is there.
- a thickener that is capable of binding to contaminants such as proteins and dispersing in high-density organic liquids is used. Used.
- Bentonite organic derivatives include organic derivatives of smectite clay, organic derivatives of hectolite clay, organic variants of montmorinite clay, refined smectite excavated soil, specially treated smectite clay, refined organic mineral clay, etc. Can be used.
- the thixotropic agent used in the present invention as a thixotropic agent may be BENT0NE 27 (a product of NEL's INDUSTRY TRIZ 'INCORPORATED, a product of thixotropic and gelling agents).
- BENT0NE 34 (trade name of thixtrobe and gelling agent manufactured by N.L.Industry.Incorporated)
- BENT0NE 38 (trade name of N.L.Industrie.Ind.
- BENTONE SD-1 (trade name of thixotropic and gelling agent made by Teddo)
- BENTONE SD-1 (trade name of thixotropic and gelling agent made by N'L'Industrials Inc.) -2 (trade name of Chixsotrobe and gelling agent manufactured by N.L.Industrie's Incorporated)
- BENTONE SD-3 (N.L.Industrie's Inco.) Poretetsu de trade name of thixotropic hydrotrope and gelling agents) and the like can ⁇ Geru be a good apply the.
- organically modified montmorillinite clay used as the thixotropic agent of the present invention BENTONE 128 (available from N.L.Industrials Inc. Inc., thixotropic and gelling agents) Brand name), BNT0NE 500 (trade name of thixotrope and gelling agent, manufactured by N.L.Industrials Inc.), MACAL0ID as purified smectite clay, specially treated smectite Examples of tit clay include BENTONE EW (trade name of thixotrope and gelling agent manufactured by N.L.Industrials Incorporated), and BENTONE LT (purified organic mineral clay). L'Industrie's Incorporated, trade names of thixotropic and gelling agents).
- Examples of the organic derivative of smectite used as the thixotropic agent in the present invention include BENTONE 34 (manufactured by N.L.Industry's Incorporated, a product of thixotropic and gelling agents). Name), BENTONE SD-3 (trade name of thixotrope and gelling agent manufactured by N.L.Industrie Trids, Inc.), BENTONE LT (trade name of N.L. Brand name, thixotropic and gelling agents), BENTONE EW Stride's Inc., trade names of thixotropic and gelling agents), MACAL0ID and the like.
- the thixotropic agent used in the present invention can be used as long as it forms a non-fluid aggregate layer in the present invention, and is not limited to the above-mentioned agent.
- the organic liquid having a high specific gravity referred to in the present invention is suitably an organic liquid having a density (gem- 3 ) of insoluble in water or insoluble of 1.05 or more.
- Inorganic compounds such as carbon tetrachloride and carbon disulfide are preferably used as high-density organic liquids, chloroform, 1,2-dichloroethane, 1,2-dibromoethane, trichloroethylene, tetrachloroethylene, cyclobenzene, bromo.
- Halogen compounds such as benzene and 0-dichlorobenzene, alcohols such as 2,2,2-trifluoroethanol and phenol, aldehydes such as furfural, acid derivatives such as propylene carbonate and triethyl phosphate, and nitros such as nitromethane and nitrobenzene
- sulfur compounds such as compounds and sulfolane.
- Suitable alcohols to be added as stabilizers for the above-mentioned high specific gravity organic liquids include methanol, ethanol, 1-propanol, 2-propanol, isoamyl phenol, 1-butanol, 2-butanol, isobutyl alcohol, and hexanol.
- Aqueous liquids for eluting nucleic acids in the upper layer include water or inorganic salts such as sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium acetate, ammonium chloride, ammonium acetate, ammonium sulfate, and dimethylachloride.
- An organic salt such as min, trimethylamine hydrochloride or the like is used as an aqueous solution, and it is usually preferable to use it at a concentration in the range of about 0.1M to 10.0M. At this time, 0.01 to 10% of a suitable anionic surfactant or nonionic surfactant may be added to the aqueous solution to increase the nucleic acid recovery rate.
- the ratio of the high-density organic liquid layer to the aqueous liquid layer is about 1: 5 to 5: 1, and these layers are mixed, and the lower high-density organic layer is formed by the cohesive layer at the interface formed by centrifugation. It is distributed between the liquid layer and the upper aqueous liquid layer, and the aqueous solvent layer (upper layer) is taken out by tilt (decantation).
- the coprecipitant of the present invention can be added alone or together with another coprecipitant at any stage in the nucleic acid extraction operation.
- the destruction of the above-mentioned biological material is usually performed in a buffer solution containing a chelating agent (PH5 to 9), and then, usually about 0.1% to 10.0% (W / V) at a concentration in the range of yin and non-ionic surfactants and a protein denaturant such as about 1M to 5M guanidine thiosinate or about 1M to 5M guanidine hydrochloride. Processing. In some cases, treatment with an enzyme for destroying cell membranes, cell walls, and the like may be performed.
- membranes such as lysozyme, achromopeptidase, lysostaphin, lyticase, and mutanolicin at a concentration of about 1 mg / ml to 50 mg / ml are used.
- lysing agent there may be protein denaturing agents at concentrations of about 10 g / ml to 20 mg / ml, such as protease K, pronase, pepsin, pabine and the like.
- the biological material is dissolved in an aqueous solution containing the above-described chelating agent, membrane solubilizing agent, protein denaturing agent, and the like, and nucleic acid and various biological substances are solubilized in the aqueous solution.
- protein removal operations can be roughly classified into two methods: a phase partitioning method using funinol or thixotropic agent and a method of solubilizing proteins.
- water-saturated phenol or buffer-saturated phenol is used to remove proteins by utilizing the protein denaturing action of phenol and its ability to separate into two layers from an aqueous solution.
- protein removal operation using a thixotropic thickener is carried out by using a high-density organic liquid containing a thixotropic thickener, a mixture of high-density organic liquids, or a mixture of these high-density organic liquids and alcohol.
- An aqueous liquid for extracting the mixture and nucleic acid to the upper layer is added to the solubilized biological material, mixed, and then centrifuged.
- protein The thixotropic agent which is combined with contaminants such as quality, is collected in the middle layer (interface) by the centrifugal force generated by centrifugation and the buoyancy of the high-density organic liquid.
- the concentration of the thixotropic agent increases, and a change in viscosity accompanying the thickening effect forms a non-flowable coagulated layer, which removes proteins by decantation.
- the water solubility of hydrophobic molecules such as proteins is increased by using a monovalent anion with a large ionic radius, such as iodine ion (I-) or chaotropic ion such as trifluoroacetic acid ion (CF 3 C00-).
- I- iodine ion
- chaotropic ion such as trifluoroacetic acid ion
- the above-mentioned procedure (3) for separating and concentrating nucleic acid using alcohol is performed, for example, by adding an equal volume of 100% isopropanol (final concentration: 50%) or a double volume of 100% ethanol (The nucleic acid may be separated and concentrated by adding a final concentration of 70%.
- the washing and purifying operation of the nucleic acid with the alcohol described in (2) above may be performed by washing and purifying the nucleic acid by adding 70% ethanol.
- HCV-RNA is a nucleic acid of a virus that causes hepatitis C and liver cancer.
- FIG. 1 is a drawing showing a procedure of separating an aqueous liquid layer containing nucleic acids in the overturning fractionation according to the method of the present invention, and is a drawing showing a separation state of an upper layer and a lower layer in a microtube.
- Fig. 2 shows the procedure for separating the aqueous liquid layer containing nucleic acids by overturning fractionation according to the method of the present invention, in which a non-flowable condensed layer is formed at the interface between the upper and lower layers in a microtube.
- FIG. 3 is a view showing a procedure of separating an aqueous liquid layer containing nucleic acids by the method of the present invention by overturning fractionation, in which the upper layer is transferred to a new microtube by the overturning fractionation operation.
- FIG. 4 is a drawing showing a procedure for separating and concentrating an aqueous liquid containing nucleic acids according to the method of the present invention, and showing a state in which alcohol is added to the aqueous liquid containing nucleic acids.
- FIG. 5 shows a procedure for separating and concentrating an aqueous liquid containing nucleic acids according to the method of the present invention.
- 1 is a drawing showing a state of formation of a precipitate of a coprecipitant and a nucleic acid.
- FIG. 6 shows a procedure for separating and concentrating an aqueous liquid containing nucleic acids according to the method of the present invention, and is a drawing showing a state in which the mixed liquid is discarded from the state shown in FIG. BEST MODE FOR CARRYING OUT THE INVENTION
- HCV-RN a was out folding, and centrifuged for 15 min at 12,000 r P m (4 Te), the supernatant was removed, Perez Doo (HCV-RNA attached to the bottom of the microtube is blue Add 70% ethanol and visually mix as a co-precipitate) Then centrifuge at 12,000r Pm for 10 minutes (4), and remove the supernatant (HCV-RNA is a blue co-precipitate). Then, it was dried under reduced pressure for about 5 minutes, dissolved in sterile double-distilled water, and subjected to a cDNA synthesis reaction using this solution, followed by a two-step PCR method. PCR products were stained with ethidium reagent after 2% agarose gel electrophoresis. The extraction efficiency was confirmed based on the presence or absence of the band, and the results are shown in Table 2.
- the above cDNA synthesis reaction was performed using a master mix (prepared in advance) for the HCR-UNA extraction fraction. Master Mix.) [Sterile distilled water 3.75 1, 5X rst strand buffer 2 1,2.5mM dNTPmixture 2 / 1,0.1 Emdity (MDTT) 1, lOpraol Anti After adding 0.5 ⁇ I of Sense Primer and reacting at 70'C for 1 minute and at 55'C for 1 minute, the mixture was quenched and quenched, and then RNasin (produced by Bromega (Promega)). 0.5 ⁇ , MMLV reverse transcriptase (manufactured by Bier L (BRL)) 0.25 / 1 was added, and the reverse transcription reaction was performed at 37 ° C. for 30 minutes and at 95 ° C. for 5 minutes.
- MMLV reverse transcriptase manufactured by Bier L (BRL)
- the total amount of synthesized cDNA (10 1) was added to a 10X reaction buffer (2.5 to 2.5 mM) using a 2.5 mM DNTP mixture (dNTPmixture) 21, sterile distilled water 10.2 1, lOpmol sensprimer 0.25 1,5 U / ⁇ I Taq DNA polymerase (Takara Shuzo Co., Ltd.)
- First (1st) PCR was performed at 72'C for 1 minute for 30 cycles.
- HCV-RNA was visually confirmed as a blue coprecipitate from the precipitation operation using isopropyl alcohol. Also, as shown in Table 1, even in the recovery, it was possible to extract a synthetic HC V- RNA of reliably 1 0 1 Covey.
- Example 1 The same experiment as in Example 1 was conducted except that the coprecipitant (amylopectin azul) of the present invention was not added, and the results are shown in Table 1.
- the nucleic acid could not be visually observed in the separation and concentration operation of the nucleic acid using isopropyl alcohol.
- Table 1 Extraction limit test by serum dilution of synthetic HCV-RNA
- Example 1 The 1.5 ml microtube used in Example 1 above was replaced with a 2.2 ml micro ⁇ tube, and instead of 600% I 100% isopropyl alcohol, 1200 ml was used. HCV-RNA was extracted in the same manner as in Example 1 by adding 100% ethanol of 1 above.
- HCV-RNA could be visually confirmed as a blue coprecipitate from the precipitation operation using 100% ethanol.
- the synthetic HCV-RNA of 10 ′ coby was able to be reliably extracted (Table 2).
- the supernatant HCV-RJiA can be visually confirmed as a blue coprecipitate.
- the mixture is dried under reduced pressure for about 5 minutes and dissolved in sterile double distilled water. After that, a two-step PCR method was performed. After gel electrophoresis, stain with ethidium gel The extraction efficiency was confirmed.
- Example 1 The 1.5 ml microtube used in Example 1 above was replaced with a 2.2 ml micro-neck tube, and instead of 600 l of 100% 100% isopropyl alcohol, 1200 ⁇ l Then, 100% ethanol was added, and HCV-RNA was extracted using the same HCV patient serum as in Example 1.
- HCV-RNA was visually confirmed as a blue coprecipitate from the precipitation operation using 100% ethanol. Also in recovery, it was possible to extract the H CV RN A from sera of patients reliably 1 0 5-fold dilutions (Table 4). Table 4
- HCV-RNA was visually confirmed as a blue co-precipitate from the precipitation operation by the coal.
- the recovery was equivalent to or higher than the AGPC method of Comparative Example 2 (Table 5).
- Example 5 An experiment was performed under the same conditions as in Example 5 except that the coprecipitant (amylopectin azul) of the present invention was not added, and the results are shown in Table 5. The precipitate in this comparative example was not visible.
- Example 5 The same experiment as in Example 5 was carried out except that amilopectin was used instead of amilopectin azul. In the separation and concentration with 100% isoprovir alcohol, H C V—R NA was confirmed as a white coprecipitate. The recovery was also the same as in Example 5.
- Fig. 1 shows an aqueous solution 11 in which impurities other than nucleic acids and nucleic acids are dispersed due to denaturation of protein contaminants at the same time as destruction of biological material,
- aqueous solution 11 in which impurities other than nucleic acids and nucleic acids are dispersed due to denaturation of protein contaminants at the same time as destruction of biological material
- FIG. 5 is a drawing showing a state in which a mixture of an organic liquid having a high specific gravity and an alcohol is separated into a microphone ⁇ tube # 1.
- FIG. 2 shows the upper layer 13 of the aqueous liquid containing DNA, and the thixotropic agent bound to proteins etc. is collected in the middle layer (boundary) by centrifugal force generated by centrifugation and the buoyancy of the organic liquid with high specific gravity.
- the concentration of the thixotropic agent increases, and the non-fluid coagulation layer 14 formed by the change in viscosity due to the thickening effect, and a high specific gravity organic liquid or a high specific gravity containing contaminants such as proteins
- FIG. 2 is a drawing showing a state of being separated into a lower layer 15 of a mixture of organic liquids or a mixture of these organic liquids having a high specific gravity and an alcohol.
- Figure 3 shows the state in which the upper layer 13 of the aqueous liquid containing DNA is transferred to a new microtube # 2 by decantation.
- FIG. 4 is a drawing showing a state in which an alcohol 16 is added to an aqueous liquid 13 containing a nucleic acid (DNA) transferred to a microtube 2.
- the two are mixed to form a mixed liquid 18, which is further centrifuged.
- a colored precipitate (coprecipitant + nucleic acid) 17 adheres to the bottom of the microtube # 2.
- FIG. 6 is a drawing showing a state in which the mixed liquid 18 is discarded, and only the colored precipitate 17 remains in the microtube # 2.
- the coprecipitant of the present invention may be added at any stage in FIGS. Industrial applicability
- the co-precipitant is added at any stage of each extraction procedure to ensure the isoproyl alcohol precipitation and ethanol precipitation.
- the presence of HCV-RNA can be confirmed visually as a blue precipitate, which has the effect of minimizing technical errors that occur during the extraction operation.
- the present invention is, of course, not limited to use in Sepagene-1 RV [Nucleic acid extraction reagent manufactured by Sanko Junyaku Co., Ltd.], but also in isopropyl alcohol precipitation in the AGPC method used as a control and other extraction methods.
- the presence of HCV-RNA can be confirmed visually as a blue precipitate during precipitation or ethanol precipitation. Since the coprecipitant according to the present invention exhibits the same behavior as HCV-RNA in the operation of recovering HCV-RNA at each extraction step, the recovery rate of HCV-RNA is improved.
- the coprecipitant according to the present invention does not compete with the reverse transcription reaction or the PCR reaction and / or does not inhibit those reactions, and therefore does not affect the detection sensitivity by these reactions.
- a non-fluidized cohesive layer is formed at the interface between the upper layer and the lower layer, so that the boundary interface becomes clear.
- the aqueous liquid layer that diffuses in the upper layer due to inclination (decantion) is formed. Can be easily separated.
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP09505013A JP3108105B2 (ja) | 1995-08-21 | 1996-08-09 | 共沈剤及び核酸の抽出方法 |
US08/817,101 US6815541B1 (en) | 1995-08-21 | 1996-08-09 | Coprecipitant and method for extracting nucleic acids |
DE1996632904 DE69632904T2 (de) | 1995-08-21 | 1996-08-09 | Kopräzipitat und methode zur extraktion von nukleinsäuren |
EP96926615A EP0792932B1 (en) | 1995-08-21 | 1996-08-09 | Coprecipitant and method of extracting nucleic acids |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7/211862 | 1995-08-21 | ||
JP21186295 | 1995-08-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997007207A1 true WO1997007207A1 (fr) | 1997-02-27 |
Family
ID=16612845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1996/002263 WO1997007207A1 (fr) | 1995-08-21 | 1996-08-09 | Co-precipitant et procede d'extraction d'acides nucleiques |
Country Status (5)
Country | Link |
---|---|
US (1) | US6815541B1 (ja) |
EP (1) | EP0792932B1 (ja) |
JP (1) | JP3108105B2 (ja) |
DE (1) | DE69632904T2 (ja) |
WO (1) | WO1997007207A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7144713B1 (en) | 1995-10-02 | 2006-12-05 | Emd Biosciences, Inc. | Method for precipitating nucleic acid with visible carrier |
JP2012235743A (ja) * | 2011-05-12 | 2012-12-06 | Sumitomo Osaka Cement Co Ltd | Rna検出用試薬およびrna検出方法 |
JP2012235716A (ja) * | 2011-05-10 | 2012-12-06 | Eiji Konishi | Rna検出用試薬およびrna検出方法 |
WO2016117663A1 (ja) * | 2015-01-21 | 2016-07-28 | 味の素株式会社 | 沈殿促進剤およびそれを用いる沈殿化方法 |
US11572581B2 (en) | 2002-06-07 | 2023-02-07 | DNA Genotek, Inc. | Compositions and methods for obtaining nucleic acids from sputum |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997012994A1 (en) * | 1995-10-02 | 1997-04-10 | Novagen, Inc. | Method for precipitating nucleic acid with visible carrier |
US7081366B2 (en) * | 2003-06-02 | 2006-07-25 | Northrop Grumman Corporation | Uniform bead dosing from a stable dispersion |
US8686129B2 (en) * | 2007-03-20 | 2014-04-01 | Agilent Technologies, Inc. | Methods for the separation of biological molecules using sulfolane |
EP2721140B1 (en) | 2011-06-19 | 2016-11-23 | Abogen, Inc. | Devices, solutions and methods for sample collection |
CN103571824B (zh) | 2012-08-09 | 2016-04-13 | 财团法人工业技术研究院 | 用于分离核酸的组合物及方法 |
IN2015DN02893A (ja) | 2012-10-04 | 2015-09-11 | Univ Leland Stanford Junior | |
US20200316493A1 (en) * | 2016-05-31 | 2020-10-08 | Dna Genotek Inc. | A composition, system and method for removal of detergents from aqueous solutions |
CN111254138A (zh) * | 2018-12-03 | 2020-06-09 | 北京银丰鼎诚生物工程技术有限公司 | 一种分子克隆中提高酶切产物浓缩效率的方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0231696A (ja) * | 1988-04-21 | 1990-02-01 | Microprobe Corp | 核酸抽出方法 |
JPH0646856A (ja) * | 1992-07-27 | 1994-02-22 | Sanko Junyaku Kk | 核酸抽出方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2588383B1 (fr) * | 1985-10-04 | 1988-01-08 | Inst Nat Sante Rech Med | Nouveau procede de recuperation et de dosage de microquantites d'acide desoxyribonucleique dans un liquide biologique acellulaire |
CA2087105C (en) * | 1990-07-13 | 2000-09-12 | Jeffrey Van Ness | Non-corrosive composition and methods useful for the extraction of nucleic acids |
DE69402076T2 (de) * | 1993-07-08 | 1997-10-16 | Tepnel Medical Ltd | Herstellung von nukleinsäuren |
JP3451667B2 (ja) * | 1993-08-24 | 2003-09-29 | 東ソー株式会社 | 核酸抽出及び特定核酸配列の検出方法 |
-
1996
- 1996-08-09 WO PCT/JP1996/002263 patent/WO1997007207A1/ja active IP Right Grant
- 1996-08-09 US US08/817,101 patent/US6815541B1/en not_active Expired - Fee Related
- 1996-08-09 DE DE1996632904 patent/DE69632904T2/de not_active Expired - Fee Related
- 1996-08-09 EP EP96926615A patent/EP0792932B1/en not_active Expired - Lifetime
- 1996-08-09 JP JP09505013A patent/JP3108105B2/ja not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0231696A (ja) * | 1988-04-21 | 1990-02-01 | Microprobe Corp | 核酸抽出方法 |
JPH0646856A (ja) * | 1992-07-27 | 1994-02-22 | Sanko Junyaku Kk | 核酸抽出方法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP0792932A4 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7144713B1 (en) | 1995-10-02 | 2006-12-05 | Emd Biosciences, Inc. | Method for precipitating nucleic acid with visible carrier |
US7550447B2 (en) | 1995-10-02 | 2009-06-23 | Merck Patent Gmbh | Method for precipitating nucleic acid with visible carrier |
US11572581B2 (en) | 2002-06-07 | 2023-02-07 | DNA Genotek, Inc. | Compositions and methods for obtaining nucleic acids from sputum |
JP2012235716A (ja) * | 2011-05-10 | 2012-12-06 | Eiji Konishi | Rna検出用試薬およびrna検出方法 |
JP2012235743A (ja) * | 2011-05-12 | 2012-12-06 | Sumitomo Osaka Cement Co Ltd | Rna検出用試薬およびrna検出方法 |
WO2016117663A1 (ja) * | 2015-01-21 | 2016-07-28 | 味の素株式会社 | 沈殿促進剤およびそれを用いる沈殿化方法 |
JPWO2016117663A1 (ja) * | 2015-01-21 | 2017-11-02 | 味の素株式会社 | 沈殿促進剤およびそれを用いる沈殿化方法 |
US10464966B2 (en) | 2015-01-21 | 2019-11-05 | Ajinomoto Co., Inc. | Precipitation promoter and precipitation method in which same is used |
JP2020117534A (ja) * | 2015-01-21 | 2020-08-06 | 味の素株式会社 | 沈殿促進剤およびそれを用いる沈殿化方法 |
CN113717239A (zh) * | 2015-01-21 | 2021-11-30 | 味之素株式会社 | 沉淀促进剂以及使用其的沉淀方法 |
Also Published As
Publication number | Publication date |
---|---|
EP0792932A4 (en) | 1999-10-20 |
DE69632904D1 (de) | 2004-08-19 |
EP0792932B1 (en) | 2004-07-14 |
EP0792932A1 (en) | 1997-09-03 |
DE69632904T2 (de) | 2004-11-18 |
JP3108105B2 (ja) | 2000-11-13 |
US6815541B1 (en) | 2004-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Emaus et al. | Nucleic acid extraction: Fundamentals of sample preparation methodologies, current advancements, and future endeavors | |
US5990302A (en) | Method for isolating ribonucleic acid | |
JP5576363B2 (ja) | 短鎖核酸を単離する方法 | |
EP1529841B1 (en) | RNA extraction method, RNA extraction reagent, and method for analyzing biological materials | |
JP4792150B2 (ja) | 核酸ハイブリダイゼーションの阻害剤を減少する方法 | |
Klein et al. | Comparison of methods for extraction of nucleic acid from hemolytic serum for PCR amplification of hepatitis B virus DNA sequences | |
US9006420B2 (en) | Method for concentrating and isolating biomolecules or viruses | |
WO1997007207A1 (fr) | Co-precipitant et procede d'extraction d'acides nucleiques | |
CN101124321A (zh) | 用于从稳定剂中纯化核酸的组合物和方法 | |
JPH09327291A (ja) | Rnaの抽出精製方法 | |
JP4025399B2 (ja) | 核酸の回収方法及び装置 | |
JP3082908B2 (ja) | リボ核酸の単離方法 | |
JP2008220377A6 (ja) | 表面における核酸の単離及び精製のための方法並びに手段 | |
JP2003235555A (ja) | 一本鎖核酸および/または二本鎖核酸の単離方法 | |
Thatcher | Nucleic acid isolation | |
US7786295B2 (en) | Method to isolate DNA | |
JP4271273B2 (ja) | 核酸ハイブリダイゼーションの阻害物質を減少させる方法 | |
JP3588370B2 (ja) | 血液成分からのウイルス核酸抽出キットおよび該試薬を用いるウイルス核酸抽出方法 | |
JP4831725B2 (ja) | 簡易的核酸抽出法 | |
JP2548494B2 (ja) | 核酸抽出方法 | |
JP2002528093A (ja) | 表面における核酸の単離及び精製のための方法並びに手段 | |
JP2001139593A (ja) | 粒子担体を使用する改良された核酸の抽出方法 | |
EP1487977B1 (en) | Method to isolate dna | |
JPH07238101A (ja) | 新規共沈剤による核酸収集法および核酸収集用キット | |
JPH11196869A (ja) | リボ核酸の単離方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996926615 Country of ref document: EP Ref document number: 08817101 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1996926615 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996926615 Country of ref document: EP |